[{"id":"0259c6da-60cc-4165-a7fc-adacc10727ab","acronym":"NCI-2018-00438","url":"https://clinicaltrials.gov/study/NCT03552471","created_at":"2021-01-18T17:29:09.671Z","updated_at":"2025-02-25T15:10:50.793Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03552471 - NCI-2018-00438","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 06/24/2022","primary_completion_date":" 06/24/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2025-02-13"},{"id":"ad06fa71-03dc-48f4-9028-17663843a88f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873962","created_at":"2021-01-18T14:06:38.922Z","updated_at":"2025-02-25T14:36:36.049Z","phase":"Phase 2","brief_title":"A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib","source_id_and_acronym":"NCT02873962","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 11/10/2016","start_date":" 11/10/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-10-30"},{"id":"fce3d556-d1c0-4ebd-973c-c01efbeeac27","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT02678182","created_at":"2021-01-17T17:56:06.364Z","updated_at":"2025-02-25T14:57:30.468Z","phase":"Phase 2","brief_title":"Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","source_id_and_acronym":"NCT02678182 - PLATFORM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Imfinzi (durvalumab) • capecitabine • Rubraca (rucaparib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 494","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-19"},{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"ffbe1180-1344-4782-86e6-9a29a87d3dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03911453","created_at":"2021-01-18T19:15:05.344Z","updated_at":"2024-07-02T16:34:59.716Z","phase":"Phase 1","brief_title":"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors","source_id_and_acronym":"NCT03911453","lead_sponsor":"University of Arizona","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • HRD • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • HRD • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-31"},{"id":"cdacc270-2f12-47f1-ad69-ceb4bc5981ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337087","created_at":"2021-01-18T16:29:08.233Z","updated_at":"2024-07-02T16:35:02.682Z","phase":"Phase 1/2","brief_title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","source_id_and_acronym":"NCT03337087","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/02/2018","start_date":" 11/02/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2024-05-17"},{"id":"784f7253-5a1d-4544-9fbf-f9c89407e818","acronym":"BrUOG 360","url":"https://clinicaltrials.gov/study/NCT04253262","created_at":"2021-01-18T20:40:05.687Z","updated_at":"2025-02-25T17:24:31.844Z","phase":"Phase 1/2","brief_title":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT04253262 - BrUOG 360","lead_sponsor":"Brown University","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" BRIP1 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRIP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-05"},{"id":"e9a0c2de-92c2-4b8a-8b7f-5e473ce5f549","acronym":"ARIANES","url":"https://clinicaltrials.gov/study/NCT04276376","created_at":"2023-01-23T18:00:08.144Z","updated_at":"2024-07-02T16:35:12.843Z","phase":"Phase 2","brief_title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","source_id_and_acronym":"NCT04276376 - ARIANES","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Suspended","enrollment":" Enrollment 130","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-26"},{"id":"2f22aa18-755d-413d-9da7-9cb6d892af4b","acronym":"TRITON3","url":"https://clinicaltrials.gov/study/NCT02975934","created_at":"2021-01-18T14:37:50.152Z","updated_at":"2024-07-02T16:35:13.638Z","phase":"Phase 3","brief_title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02975934 - TRITON3","lead_sponsor":"pharmaand GmbH","biomarkers":" BRCA1 • BRCA2 • ATM • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • ATM • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 405","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 08/25/2022","primary_completion_date":" 08/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-20"},{"id":"7235b2f2-0818-493f-a41a-c34684bbba42","acronym":"TRIUMPH","url":"https://clinicaltrials.gov/study/NCT03413995","created_at":"2021-01-18T16:50:34.963Z","updated_at":"2024-07-02T16:35:19.977Z","phase":"Phase 2","brief_title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","source_id_and_acronym":"NCT03413995 - TRIUMPH","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-09"},{"id":"6e1abb23-1116-4eb5-9ab8-6b55731a123c","acronym":"NCI-2018-00016","url":"https://clinicaltrials.gov/study/NCT03442556","created_at":"2021-01-18T16:58:40.512Z","updated_at":"2024-07-02T16:35:22.192Z","phase":"Phase 2","brief_title":"Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency","source_id_and_acronym":"NCT03442556 - NCI-2018-00016","lead_sponsor":"University of Washington","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/24/2018","start_date":" 08/24/2018","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2024-01-25"},{"id":"62e0eee9-22db-44d4-a223-d40e26e7037a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03958045","created_at":"2023-12-22T16:16:39.966Z","updated_at":"2024-07-02T16:35:25.419Z","phase":"Phase 2","brief_title":"Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma","source_id_and_acronym":"NCT03958045","lead_sponsor":"Zhonglin Hao","biomarkers":" PD-L1 • TMB","pipe":"","alterations":" ","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-12-22"},{"id":"0a4f94d2-46dc-4d75-9e6a-d30cc9f79e51","acronym":"CASPAR","url":"https://clinicaltrials.gov/study/NCT04455750","created_at":"2023-12-09T16:53:24.247Z","updated_at":"2024-07-02T16:35:27.217Z","phase":"Phase 3","brief_title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","source_id_and_acronym":"NCT04455750 - CASPAR","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Rubraca (rucaparib) • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-04"},{"id":"b5f677ab-53f6-4549-8ee9-29923b7542ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03840200","created_at":"2021-01-18T18:57:28.084Z","updated_at":"2024-07-02T16:35:31.269Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","source_id_and_acronym":"NCT03840200","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • MUC16","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2023-10-30"},{"id":"a7424bb1-6096-4c3e-be6f-e97cac03af01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03542175","created_at":"2021-01-18T17:25:46.146Z","updated_at":"2024-07-02T16:35:41.269Z","phase":"Phase 1","brief_title":"A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy","source_id_and_acronym":"NCT03542175","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 07/25/2024","primary_completion_date":" 07/25/2024","study_txt":" Completion: 07/25/2024","study_completion_date":" 07/25/2024","last_update_posted":"2023-08-02"},{"id":"254d16be-4464-4b78-b319-213ecb8bd23e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02042378","created_at":"2021-01-18T09:22:46.324Z","updated_at":"2024-07-02T16:35:45.837Z","phase":"Phase 2","brief_title":"A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation","source_id_and_acronym":"NCT02042378","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2023-06-13"},{"id":"b83a9963-8f7c-43e0-99c2-f53bfa2111a8","acronym":"ARIEL2","url":"https://clinicaltrials.gov/study/NCT01891344","created_at":"2021-01-17T17:24:51.196Z","updated_at":"2024-07-02T16:35:45.987Z","phase":"Phase 2","brief_title":"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)","source_id_and_acronym":"NCT01891344 - ARIEL2","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 491","initiation":"Initiation: 10/30/2013","start_date":" 10/30/2013","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 09/28/2021","study_completion_date":" 09/28/2021","last_update_posted":"2023-06-12"},{"id":"0a60cbe9-deb3-4933-a0bf-b4daf62da8a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01482715","created_at":"2021-01-18T06:11:36.631Z","updated_at":"2024-07-02T16:35:46.101Z","phase":"Phase 2","brief_title":"A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)","source_id_and_acronym":"NCT01482715","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2023-06-09"},{"id":"2a486036-459d-4e33-93ca-b0c39b56d68a","acronym":"ARIEL3","url":"https://clinicaltrials.gov/study/NCT01968213","created_at":"2021-01-17T17:24:49.542Z","updated_at":"2024-07-02T16:35:46.105Z","phase":"Phase 3","brief_title":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","source_id_and_acronym":"NCT01968213 - ARIEL3","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 564","initiation":"Initiation: 04/07/2014","start_date":" 04/07/2014","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 07/07/2022","study_completion_date":" 07/07/2022","last_update_posted":"2023-06-09"},{"id":"33e6efe3-69ef-47f0-b007-a45c428903e9","acronym":"TRITON2","url":"https://clinicaltrials.gov/study/NCT02952534","created_at":"2021-01-17T17:39:04.239Z","updated_at":"2024-07-02T16:35:46.027Z","phase":"Phase 2","brief_title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02952534 - TRITON2","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 02/15/2017","start_date":" 02/15/2017","primary_txt":" Primary completion: 07/18/2021","primary_completion_date":" 07/18/2021","study_txt":" Completion: 07/27/2021","study_completion_date":" 07/27/2021","last_update_posted":"2023-06-09"},{"id":"5b05c638-c1bf-4e7c-83ce-7ef5bd53b4b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499444","created_at":"2021-01-18T17:13:39.540Z","updated_at":"2024-07-02T16:35:46.086Z","phase":"Phase 1","brief_title":"A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor","source_id_and_acronym":"NCT03499444","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/06/2018","start_date":" 02/06/2018","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 04/13/2022","study_completion_date":" 04/13/2022","last_update_posted":"2023-06-09"},{"id":"689fe11c-4baf-44b7-84e8-473969896672","acronym":"ARIEL4","url":"https://clinicaltrials.gov/study/NCT02855944","created_at":"2021-01-17T17:24:52.714Z","updated_at":"2024-07-02T16:35:46.070Z","phase":"Phase 3","brief_title":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","source_id_and_acronym":"NCT02855944 - ARIEL4","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • paclitaxel • Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 349","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 12/03/2020","primary_completion_date":" 12/03/2020","study_txt":" Completion: 09/16/2022","study_completion_date":" 09/16/2022","last_update_posted":"2023-06-09"},{"id":"8f96cd3a-f8f6-4456-af45-b6431c80570f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02986100","created_at":"2021-01-18T14:41:25.041Z","updated_at":"2024-07-02T16:35:46.097Z","phase":"Phase 1","brief_title":"Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib","source_id_and_acronym":"NCT02986100","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2023-06-09"},{"id":"8eae4547-c419-42bc-bcef-a0c556fe5a48","acronym":"REVOCAN","url":"https://clinicaltrials.gov/study/NCT04826198","created_at":"2021-04-01T16:52:33.019Z","updated_at":"2024-07-02T16:35:51.390Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months","source_id_and_acronym":"NCT04826198 - REVOCAN","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA • MUC16","pipe":"","alterations":" ","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • AsiDNA (etidaligide)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-04-05"}]